Linagliptin Inpatient Trial

NCT02004366 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

295

Enrollment

OTHER

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: Linagliptin
DRUG: Basal Bolus
DRUG: Linagliptin
DRUG: Linagliptin + 50% Glargine dose on discharge
DRUG: Linagliptin + 80% Glargine

Sponsor

Emory University

Collaborators

[object Object]
[object Object]
[object Object]